Our executive director, Emmanuelle Toussaint, at BIOQuébec had the honor of participating to the “Rendez-Vous Politique de la Fédération des chambres de commerce du Québec (FCCQ)” with Canada’s Minister of Health, Jean-Yves Duclos
Read More
Quebec is rich in innovative companies that strive to do things differently to bring our knowledge and skills to another level. We were delighted to honor our members Jenthera Therapeutics, Repare Therapeutics, Ventus Therapeutics, KisoJi Biotechnology, Valence Discovery and Modelis who all innovate in the field of life sciences for the development of new therapies.
Read More
BIOquébec is proud to announce the winner of the Gala des Prix Innovation 2022 in the "Life Sciences" category: Innodal ! We are delighted to have such an innovative company among our members, that is innovating with a new generation of antimicrobials to improve food safety standards and meets the consumer’s demands. The ’’Prix Coup de Cœur ‘’ goes to Paperplane Therapeutics who designs therapeutic virtual reality video games aimed at improving pain and anxiety management in children undergoing various medical treatments or procedures. Congratulations to the finalists Ditch Labs and KAT Innovation.
Read More
BROMONT, Québec--(BUSINESS WIRE)--Emmanuelle Toussaint, Executive Director at BIOQuébec, Québec's largest biotechnology and life sciences network, has been named one of Canada’s most inspiring climate leaders in the ‘Women in Energy Transformation Series’, an initiative by Women in Renewable Energy (WiRE), GLOBE Series and Pembina Institute. This award celebrates the most powerful women advancing Canada’s transition to a clean economy and identifies opportunities for more women to get involved.
Read More
Although Fragment-Based Lead Discovery (FBLD) is one of the most promising strategies for discovering future medical compounds, there are still until today barriers that discourage industry from pursuing this approach.
Read More
Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing LAU-7b (oral fenretinide) as a first-in-class inflammation-controlling drug candidate for Cystic Fibrosis (CF), announces the presentation of results from its placebo-controlled Phase 2 APPLAUD 24-week clinical study in adults with CF at the North American Cystic Fibrosis Conference (NACFC) currently held in Philadelphia, United States.
Read More
Innovative Medicines Canada’s (IMC) initial interpretation of the Patented Medicine Prices Review Board’s (PMPRB) revised draft Guidelines is that they will further reduce the availability of new medicines in Canada by exacerbating an already unpredictable regulatory environment.
Read More
The Canadian Cancer Society (CCS), CQDM, the Cole Foundation and Oncopole – pôle cancer du FRQS announced, today, grants of $8,485,132 to finance four research projects in Quebec, as part of the Pediatric Cancer Research Initiative.
Read More
ECOGENE-21, a non-profit clinical and academic research organisation dedicated to providing access to innovation for unmet health needs, including rare or severe diseases, successfully completed the first flight demonstrations of the drone delivery process for clinical trials at the Centre of Excellence on Drones (CED) in Alma on September 28.
Read More
Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of SORT1, the target for Theratechnologies’ oncology platform, in several cancer types.
Read More
Génome Québec is happy to announce today the eleven research teams, from four Québec universities, that have received major funding in genomics. The total investment, including that of public and private partners, amounts to more than $4 million as part of the first round of the Genomics integration program – Human health.
Read More
adMare BioInnovations (adMare) and Medicine by Design are pleased to announce their new memorandum of understanding (MOU) to support translation priorities, which will accelerate health innovation commercialization in the Toronto life sciences ecosystem and in Canada.
Read More
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the completion of a Series C funding of $95 million CAD (approximately $70 million USD), led by New Enterprise Associates (“NEA”).
Read More
Ventus Therapeutics, Inc. announced today that the company has entered into an exclusive worldwide license agreement with Novo Nordisk A/S to develop and commercialize candidates from Ventus’ portfolio of peripherally-restricted NLRP3 inhibitors.
Read More
In celebration of Global Biotech Week, today at the national BIONATION 2022 conference, the leaders of Genome Canada and adMare BioInnovations announced a new strategic partnership to support the translation of genomics research into commercialization opportunities in healthcare.
Genomics-enabled precision health tools are speeding up diagnoses and improving health outcomes and disease management for Canadians.
Mila – Quebec Artificial Intelligence Institute announced today that AbCellera, a Vancouver-based technology company that helps to discover new antibody-based medicines and bring them to patients faster, has joined its community of industrial partners.
Read More
Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop small molecule therapeutics across a broad range of diseases, announced today the opening of a new office and lab facility in Waltham, Massachusetts as the first phase of its planned global expansion.
Read More
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, has received FDA clearance of its Investigational New Drug (IND) application for a phase 2 study in Diabetic Kidney Disease (DKD) for INV-202, the Company’s lead program.
Read More
WIB-Greater Montreal and Executive Women In Bio (EWIB), an initiative of Women In Bio (WIB) committed to promoting, empowering, and elevating executive women in biopharma and the life sciences, are thrilled to present the 26 women who will participate in this year’s ECBG program.
Read More
GSK today announced an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to help protect Canadian adults and children. The four-year agreement, spanning through March 2026, includes the supply of as many as 80 million doses of Arepanrix (adjuvanted pandemic influenza vaccine) in the event of an influenza pandemic(s) and a minimum of 4 million doses per year of Flulaval Tetra (seasonal influenza vaccine). Both vaccines will be supplied by GSK’s Sainte-Foy, Quebec facility. This agreement follows earlier agreements between the Government of Canada and GSK to supply both pandemic and seasonal influenza vaccines dating back to 2001.
Read More